Epilepsy. Epilepsy and recurrent seizures
Conditions
Interventions
Intervention 1: Intervention group: Lacosamide (Unimide brand) was started with a daily dose of 2 mg/kg/day divided into two doses (BD) and continued with an increase of 2 mg/kg/day every week to a ma
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
4 Years to 16 Years
Inclusion criteria
Inclusion criteria: Children aged between 4 and 16 years with newly diagnosed epilepsy
Exclusion criteria
Exclusion criteria: History of liver disease and history of heart disease Receiving antiepileptic medication for more than 48 hours during the last three months Patients with any neurodegenerative or neurometabolic disease causing an allergic reaction Dissatisfaction of the patient and the patient's parents Patients with a history of bone marrow suppression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At least a period of 6 months without seizures. Timepoint: For 6 months, the number and type of seizures experienced by the child from the previous visit will be asked. Method of measurement: Observing types of seizures by parents. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug side effects includes (aplastic anemia - agranulocytosis - liver disorder (increased AST, ALT more than 5 times the normal range) - hyponatremia (Na less than 135). Timepoint: 6 months after drug intervention. Method of measurement: Observation of drug complications includes (aplastic anemia - agranulocytosis - liver dysfunction (increase of AST, ALT above 5 times the normal range) - hyponatremia (Na less than 135). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKobra Sheidaee
Mazandaran University of Medical Sciences
Outcome results
None listed